Saccharomyces boulardii

Mechanism of action

Proposed mechanisms supported by preclinical and clinical studies (variable depending on context): - Antagonism against pathogens: competition for adhesion sites and nutrients; interference with the adhesion of certain microorganisms to the mucosa. - Neutralization/inactivation of toxins: evidence for reduced activity of bacterial toxins in experimental models (e.g. C. difficile toxins) through proteases/enzymes and physical binding. - Barrier effect: support of tight junctions and reduced intestinal permeability in some models; possible increase in trophic and reparative factors of the mucosa. - Mucosal immunomodulation: modulation of cytokines and the secretory IgA response; possible reduction of pro-inflammatory signals in specific contexts. - Effects on the microbiota: it does not stably colonize, but it may transiently influence the intestinal ecosystem and resilience during stress (e.g. antibiotics).

Supported benefits

• Reduced risk of antibiotic-associated diarrhea in some populations (prevention and/or reduced duration, depending on the studies) (strong)
• Support in the prevention of traveler’s diarrhea (effect varies depending on destination, pathogens, and protocol) (moderate)
• Reduced risk of recurrence in some management strategies for Clostridioides difficile infections as an adjunctive treatment (evidence is not uniform; depends on population and concomitant therapy) (limited)
• Reduced duration of acute infectious diarrhea in some contexts (especially pediatric), with heterogeneous results (moderate)
• Improvement of some functional gastrointestinal symptoms (e.g. bloating/irregularity) in subgroups, with high individual variability (emerging)

Safety & side effects

• Bloating, flatulence, abdominal cramps, nausea (generally mild and transient).
• Constipation or changes in bowel habits in some individuals.
• Rare hypersensitivity reactions (e.g. rash).
• Rare but serious events: fungemia/systemic Saccharomyces infection, especially in high-risk individuals.

FAQ

Is it a probiotic bacterium?

No. It is a yeast (a eukaryotic organism). This difference explains, among other things, its relative resistance to antibacterial antibiotics and certain safety specifics (e.g. the rare risk of fungemia in vulnerable individuals).

Does it stably colonize the intestine?

Generally no: its presence is transient and tends to decrease rapidly after discontinuation. The observed effects therefore depend on continued intake during the studied period.

Is it useful during antibiotic use?

It is one of the most studied indications for antibiotic-associated diarrhea. However, effectiveness depends on the population, dose, strain/formulation, and individual risk; it is not appropriate for everyone (e.g. immunocompromised individuals or those with a central venous catheter).

Can it replace therapy for intestinal infections?

No. It has been studied as support/adjunctive treatment or prevention in specific contexts, but it does not replace diagnosis and medical treatments when necessary.

How do you choose a quality product?

Relevant factors include: strain identification, CFUs declared at expiry, storage conditions, quality controls, and transparency regarding excipients. Quality may vary between manufacturers.